Virus engineered to target and kill cancer cells

Wednesday, 30 January, 2019

Virus engineered to target and kill cancer cells

Scientists at Hokkaido University have engineered a virus that selectively targets and kills cancer cells, with an even stronger anticancer effect than another engineered virus currently used in clinical practice.

Some viruses can be used to treat cancers, as they replicate within the cells until they burst and die. With this in mind, molecular oncologist Professor Fumihiro Higashino and colleagues deleted a gene involved in viral replication, called E4orf6, from a type of adenovirus.

The team had previously discovered that E4orf6 stabilises a type of mRNA called ARE-mRNAs in the infected cells, enabling viral replication. ARE-mRNAs are known to be stable in stressed cells and cancer cells, but rapidly degrade in normal cells.

In laboratory tests, the team found that their modified adenovirus, called dl355, replicated and increased its number significantly more in cancer cells than it did in normal cells. As explained by Prof Higashino, “The E4orf6-lacking virus relies on the stable ARE-mRNAs in cancer cells for its replication.”

The researchers infected several types of cultured cancer cells with 100 dl355 virus particles per cell and found that nearly all the cancer cells died within seven days. In contrast, most normal cells infected with the virus did not die, even after seven days. Several cancer cell lines managed to survive low doses of dl355, but all cancer cells were killed by the virus as the dose was increased. Tumour growth was also significantly suppressed when dl355 was administered to human tumour cells grown in mice.

Comparison of cancer cells and normal cells after being infected with the dl355 adenovirus. The top four cell types listed on the left (HeLa, C33A, A549 and H1299) are cancer cells and the bottom two (BJ and WI38) are normal cells. As the amount of dl355 virus administered to the cancer cells increased (represented by MOI), more cancer cells died within seven days, while the normal cells continued to live. (Yanagawa-Matsuda, et al, Oncology Reports, November 12, 2018)

Finally, the team compared the anticancer effects of dl355 with another anticancer adenovirus currently used in clinical practice, called dl1520. dl355 replication was higher in all cancer cell lines tested, including cervical and lung cancer cells, and was better at killing all but one type of cancer cell, compared to dl1520. Both viruses only killed very few normal cells.

The findings, published in the journal Oncology Reports, suggest that dl355 has potential to be an effective anticancer treatment. The researchers suggest that enhancing the stabilisation of ARE-mRNAs in cancer cells could even further strengthen its effect, but Prof Higashino notes that further research is required.

“While we think dl355 has the potential to be an effective treatment method in dealing with many types of cancers, much more research needs to be done,” he said. “When we think of a timeline, at least five more years of further research may be required, possibly more, on top of clinical trials.”

Top image credit: ©

Follow us on Twitter and Facebook for the latest industry news. To receive our bimonthly magazine and weekly newsletters, click here.

Related News

Gut microbiome may influence HIV transmission in high-risk men

Gut microbes from high HIV-risk men drive immune activation in mice and HIV infection in cells,...

Gum bacteria implicated in Alzheimer's disease

Bacteria involved in gum disease can travel throughout the body, exuding toxins connected with...

Multigene test predicts depression risk in young people

An international research team has found a genetic score that reliably predicts the risk,...

  • All content Copyright © 2019 Westwick-Farrow Pty Ltd